Regeneration of chronic myocardial infarction by injectable hydrogels containing stem cell homing factor SDF-1 and angiogenic peptide Ac-SDKP

Biomaterials

Volumn 35, Issue 8, 2014, Pages 2436-2445

  Song, Myeongjin ^a   Jang, Hwanseok ^a,b   Lee, Jaeyeon ^a   Kim, Ji Hyun ^c   Kim, Soo Hyun ^c   Sun, Kyung ^b   Park, Yongdoo ^a,b  

^a Korea University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

Ac SDKP; Chronic heart failure; Controlled release system; Hydrogel; Matrix metalloproteinase (MMP); SDF 1

Indexed keywords

AC-SDKP; CHRONIC HEART FAILURES; CONTROLLED RELEASE SYSTEMS; MATRIX METALLOPROTEINASES; SDF-1;

CARDIOLOGY; GENE EXPRESSION; PEPTIDES; STEM CELLS;

HYDROGELS;

ANGIOGENIC FACTOR; PROTEIN AC SDKP; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HUMAN; HUMAN CELL; HYDROGEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; TISSUE REGENERATION;

AC-SDKP; CHRONIC HEART FAILURE; CONTROLLED RELEASE SYSTEM; HYDROGEL; MATRIX METALLOPROTEINASE (MMP); SDF-1;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELLS, CULTURED; CHEMOKINE CXCL12; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; HYDROGELS; MALE; MESENCHYMAL STROMAL CELLS; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGOPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CXCR4; REGENERATION; TRANSCRIPTOME; VENTRICULAR FUNCTION, LEFT;

EID: 84891738341     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.011     Document Type: Article

References (48)

1. Gheorghiade M., Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998, 97:282-289.
2. Gheorghiade M., Sopko G., De Luca L., Velazquez E.J., Parker J.D., Binkley P.F., et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation 2006, 114:1202-1213.
3. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 2003, 108:1395-1403.
4. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. JAm Coll Cardiol 2000, 35:569-582.
5. Penn M.S., Dong F., Klein S., Mayorga M.E. Stem cells for myocardial regeneration. Clin Pharmacol Ther 2011, 90:499-501.
6. Jawad H., Ali N.N., Lyon A.R., Chen Q.Z., Harding S.E., Boccaccini A.R. Myocardial tissue engineering: a review. JTissue Eng Regen Med 2007, 1:327-342.
7. Eschenhagen T., Zimmermann W.H. Engineering myocardial tissue. Circ Res 2005, 97:1220-1231.
8. Dayan V., Yannarelli G., Filomeno P., Keating A. Human mesenchymal stromal cells improve scar thickness without enhancing cardiac function in a chronic ischaemic heart failure model. Interact Cardiovasc Thorac Surg 2012, 14:516-520.
9. Sarto P., Balducci E., Balconi G., Fiordaliso F., Merlo L., Tuzzato G., et al. Effects of exercise training on endothelial progenitor cells in patients with chronic heart failure. JCard Fail 2007, 13:701-708.
10. Banquet S., Gomez E., Nicol L., Edwards-Levy F., Henry J.P., Cao R., et al. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation 2011, 124:1059-1069.
11. Segers V.F., Lee R.T. Stem-cell therapy for cardiac disease. Nature 2008, 451:937-942.
12. Heilmann C. Myocardial regeneration by stem cells: still a black box. Eur J Cardiothorac Surg 2008, 34:255.
13. Miyahara Y., Nagaya N., Kataoka M., Yanagawa B., Tanaka K., Hao H., et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006, 12:459-465.
14. Amado L.C., Saliaris A.P., Schuleri K.H., St John M., Xie J.S., Cattaneo S., et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 2005, 102:11474-11479.
15. Hall H. Modified fibrin hydrogel matrices: both, 3D-scaffolds and local and controlled release systems to stimulate angiogenesis. Curr Pharm Des 2007, 13:3597-3607.
16. Fujita M., Ishihara M., Morimoto Y., Simizu M., Saito Y., Yura H., et al. Efficacy of photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 in a rabbit model of chronic myocardial infarction. JSurg Res 2005, 126:27-33.
17. Brunner S., Winogradow J., Huber B.C., Zaruba M.M., Fischer R., David R., et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. FASEB J 2009, 23:351-361.
18. Haider H., Jiang S., Idris N.M., Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res 2008, 103:1300-1308.
19. Zhang M., Mal N., Kiedrowski M., Chacko M., Askari A.T., Popovic Z.B., et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 2007, 21:3197-3207.
20. Hu X., Dai S., Wu W.J., Tan W., Zhu X., Mu J., et al. Stromal cell derived factor-1 alpha confers protection against myocardial ischemia/reperfusion injury: role of the cardiac stromal cell derived factor-1 alpha CXCR4 axis. Circulation 2007, 116:654-663.
21. Liu X., Duan B., Cheng Z., Jia X., Mao L., Fu H., et al. SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion. Protein Cell 2011, 2:845-854.
22. Theiss H.D., Vallaster M., Rischpler C., Krieg L., Zaruba M.M., Brunner S., et al. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis. Stem Cell Res 2011, 7:244-255.
23. Levesque J.P., Hendy J., Takamatsu Y., Simmons P.J., Bendall L.J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. JClin Invest 2003, 111:187-196.
24. Zhang D., Fan G.C., Zhou X., Zhao T., Pasha Z., Xu M., et al. Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardium. JMol Cell Cardiol 2008, 44:281-292.
25. Smart N., Rossdeutsch A., Riley P.R. Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis 2007, 10:229-241.
26. Carpintero P., Anadon R., Gomez-Marquez J. Expression of the thymosin beta10 gene in normal and kainic acid-treated rat forebrain. Brain Res Mol Brain Res 1999, 70:141-146.
27. Koutrafouri V., Leondiadis L., Avgoustakis K., Livaniou E., Czarnecki J., Ithakissios D.S., et al. Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochim Biophys Acta 2001, 1568:60-66.
28. Malinda K.M., Goldstein A.L., Kleinman H.K. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J 1997, 11:474-481.
29. Wang D., Carretero O.A., Yang X.Y., Rhaleb N.E., Liu Y.H., Liao T.D., et al. N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis invitro and invivo. Am J Physiol Heart Circ Physiol 2004, 287:H2099-H2105.
30. Sellke F.W., Simons M. Angiogenesis in cardiovascular disease: current status and therapeutic potential. Drugs 1999, 58:391-396.
31. Ghajar C.M., Kachgal S., Kniazeva E., Mori H., Costes S.V., George S.C., et al. Mesenchymal cells stimulate capillary morphogenesis via distinct proteolytic mechanisms. Exp Cell Res 2010, 316:813-825.
32. Xiaozhen D., Shaoxi C., Qunfang Y., Jiahuan J., Xiaoqing Y., Xin X., et al. Anovel invitro angiogenesis model based on a microfluidic device. Chin Sci Bull 2011, 56:3301-3309.
33. Zimmermann W.H., Cesnjevar R. Cardiac tissue engineering: implications for pediatric heart surgery. Pediatr Cardiol 2009, 30:716-723.
34. Arnold S.V., Smolderen K.G., Buchanan D.M., Li Y., Spertus J.A. Perceived stress in myocardial infarction: long-term mortality and health status outcomes. JAm Coll Cardiol 2012, 60:1756-1763.
35. Traverse J.H. Using biomaterials to improve the efficacy of cell therapy following acute myocardial infarction. JCardiovasc Transl Res 2012, 5:67-72.
36. Cassino T.R., Drowley L., Okada M., Beckman S.A., Keller B., Tobita K., et al. Mechanical loading of stem cells for improvement of transplantation outcome in a model of acute myocardial infarction: the role of loading history. Tissue Eng Part A 2012, 18:1101-1108.
37. Ruvinov E., Leor J., Cohen S. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials 2011, 32:565-578.
38. Goodchild T.T., Robinson K.A., Pang W., Tondato F., Cui J., Arrington J., et al. Bone marrow-derived B cells preserve ventricular function after acute myocardial infarction. JACC Cardiovasc Interv 2009, 2:1005-1016.
39. Aronson D., Krum H. Novel therapies in acute and chronic heart failure. Pharmacol Ther 2012, 135:1-17.
40. Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000, 101:2981-2988.
41. Yoon S.J., Fang Y.H., Lim C.H., Kim B.S., Son H.S., Park Y., et al. Regeneration of ischemic heart using hyaluronic acid-based injectable hydrogel. JBiomed Mater Res B Appl Biomater 2009, 91:163-171.
42. Kim J., Kim I.S., Cho T.H., Lee K.B., Hwang S.J., Tae G., et al. Bone regeneration using hyaluronic acid-based hydrogel with bone morphogenic protein-2 and human mesenchymal stem cells. Biomaterials 2007, 28:1830-1837.
43. Park J., Lim E., Back S., Na H., Park Y., Sun K. Nerve regeneration following spinal cord injury using matrix metalloproteinase-sensitive, hyaluronic acid-based biomimetic hydrogel scaffold containing brain-derived neurotrophic factor. JBiomed Mater Res A 2010, 93:1091-1099.
44. Davis M.E., Hsieh P.C., Takahashi T., Song Q., Zhang S., Kamm R.D., et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A 2006, 103:8155-8160.
45. Yu J., Wang A., Tang Z., Henry J., Li-Ping Lee B., Zhu Y., et al. The effect of stromal cell-derived factor-1alpha/heparin coating of biodegradable vascular grafts on the recruitment of both endothelial and smooth muscle progenitor cells for accelerated regeneration. Biomaterials 2012, 33:8062-8074.
46. Huff T., Muller C.S., Otto A.M., Netzker R., Hannappel E. beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol 2001, 33:205-220.
47. Bock-Marquette I., Saxena A., White M.D., Dimaio J.M., Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004, 432:466-472.
48. Huang C., Gu H., Zhang W., Manukyan M.C., Shou W., Wang M. SDF-1/CXCR4 mediates acute protection of cardiac function through myocardial STAT3 signaling following global ischemia/reperfusion injury. Am J Physiol Heart Circ Physiol 2011, 301:H1496-H1505.